Cullen Frost Bankers Inc. bought a new position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, Holdings Channel reports. The fund bought 94,452 shares of the biopharmaceutical company’s stock, valued at approximately $17,387,000.

Several other institutional investors have also made changes to their positions in SHPG. Duncker Streett & Co. Inc. acquired a new position in shares of Shire PLC during the second quarter worth approximately $111,000. West Oak Capital LLC acquired a new position in shares of Shire PLC during the second quarter worth approximately $126,000. NEXT Financial Group Inc acquired a new position in shares of Shire PLC during the second quarter worth approximately $126,000. North Star Investment Management Corp. acquired a new position in shares of Shire PLC during the second quarter worth approximately $147,000. Finally, OLD Second National Bank of Aurora acquired a new position in shares of Shire PLC during the second quarter worth approximately $161,000. 24.26% of the stock is currently owned by institutional investors and hedge funds.

Shire PLC (NASDAQ:SHPG) traded up 0.11% on Thursday, hitting $204.22. 1,354,199 shares of the stock were exchanged. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32. The company has a market cap of $60.83 billion, a PE ratio of 42.44 and a beta of 1.11. The company’s 50-day moving average is $196.07 and its 200-day moving average is $183.99.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.35. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s quarterly revenue was up 55.9% compared to the same quarter last year. During the same period last year, the company earned $2.63 earnings per share. On average, analysts predict that Shire PLC will post $12.93 earnings per share for the current year.

The firm also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.

A number of brokerages have recently commented on SHPG. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. Zacks Investment Research cut shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, June 8th. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 14th. Sanford C. Bernstein reissued an “outperform” rating and issued a $222.00 price objective on shares of Shire PLC in a research note on Thursday, June 9th. Finally, Leerink Swann reissued a “buy” rating and issued a $213.00 price objective (down from $225.00) on shares of Shire PLC in a research note on Thursday, June 16th. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $230.67.

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.